Since the original publication of Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Allogeneic hematopoietic stem cell transplantation (HSC) has undergone several fast-paced changes. In this second edition, the editors have focused on topics relevant to evolving knowledge in the field in order to better guide clinicians in decision-making and management of their patients, as well as help lead laboratory investigators in new directions emanating from clinical observations. Some of the most respected clinicians and scientists in this discipline have responded to the recent advances in the field by providing state-of-the-art discussions addressing these topics in the second edition. The text covers the scope of human genomic variation, the methods of HLA typing and interpretation of high-resolution HLA results. Comprehensive and up-to-date, Allogeneic Stem Cell Transplantation: Clinical Research and Practice, Second Edition offers concise advice on today's best clinical practice and will be of significant benefit to all clinicians and researchers in allogeneic HSC transplantation.

This book provides a comprehensive and up-to-date review of all aspects of childhood Acute Lymphoblastic Leukemia, from basic biology to supportive care. It offers new insights into the genetic pre-disposition to the condition and discusses how response to early therapy and its basic biology are utilized to develop new prognostic stratification systems and target therapy. Readers will learn about current treatment and outcomes, such as immunotherapy and targeted therapy approaches. Supportive care and management of the condition in resource poor countries are also discussed in detail. This is an indispensable guide for research and laboratory scientists, pediatric hematologists as well as specialist nurses involved in the care of childhood leukemia.

Achildren's book about Leukemia.

A leading cancer specialist tells the compelling stories of three adult leukemia patients, shedding new light on the disease itself and the drugs developed to treat it When you are told that you have leukemia, your world stops. Your brain can’t function. You are asked to make decisions about treatment almost immediately, when you are not in your right mind. And yet you pull yourself together and start asking questions. Beside you is your doctor, whose job it is to solve the awful puzzle of bone marrow gone wrong. The two of you are in it together. In When Blood Breaks Down, Mikkael Sekeres, a leading cancer specialist, takes readers on the journey that patient and doctor travel together. Sekeres, who writes regularly for the “Well” section of The New York Times, tells the compelling stories of three people who receive diagnoses of adult leukemia within hours of each other: Joan, a 48-year-old surgical nurse, a caregiver who becomes a patient; David, a 68-year-old former factory worker who bows to his family’s wishes and pursues the most aggressive treatment; and Sarah, a 36-year-old pregnant woman who must decide whether to undergo chemotherapy and put her fetus at risk. We join the intimate conversations between Sekeres and his patients, and we watch as he teaches trainees. Along the way, Sekeres also explores leukemia in its different forms and the development of drugs to treat it—describing, among many other fascinating details, the invention of the bone marrow transplant (first performed experimentally on beagles) and a treatment that targets the genetics of leukemia. The lessons to be learned from leukemia, Sekeres shows, are not merely medical; they teach us about courage and grace and defying the odds.

Better therapy of acute leukemias depends ultimately on better understanding of the distinction between leukemic and normal progenitor cells. This hugely important new book describes the current knowledge of acute leukemia biology and discusses new classification systems that have arisen as a result of emerging insights into pathogenesis. Estey, Faderl and Kantarjian, who all work at the respected Anderson Cancer Center in Houston, Texas, USA, examine in detail advances in the treatment of particular types of acute leukemia. Their book also covers the management of acute leukemia in general as well as the development of new therapies. This book will be extremely useful to clinicians.

Something everyone has the power to do is reduce your cancer risk, and this book will show you just how easy it is to do it. Each year, over a million people in the United States alone hear the words no one ever wants to hear: You have cancer. But what if there was a way for fewer people to hear these words? One of the biggest myths regarding cancer is that it’s mostly genetic - meaning that you have no control over whether you get it. While genetics do have an impact, the truth is that your lifestyle and environment play the major role. Physician and Chief Medical Offer of WebMD John Whyte, MD, MPH, shares straightforward information and equips you with strategies to help you on a journey to better health. In Take Control of Your Cancer Risk, Dr. Whyte provides helpful tips including: assessing your cancer risk knowing which screenings you need, and when learning the role food, exercise, and sleep play understanding the relationship between stress and cancer Take Control of Your Cancer Risk is filled with practical advice that empowers you to really take control of our health.

This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of leukemia treatment. Leukemia treatment has undergone major change over the course of the past few years and Leukemia addresses current best practices in the light of the most recent evidence. With contributions from experts across the US and Canada, Leukemia details the current management of different types of leukemia and reviews new therapies in development for various forms of acute leukemia, chronic leukemia, myelodysplastic syndrome, and myeloproliferative disorders. Coverage includes new developments in hematopoitic cell transplantation, leukemia pathology and management, immunotherapy and targeted therapies. It is a valuable tool for clinicians, nurses, researchers, medical students, residents, and fellows. Emerging Cancer Therapeutics Series Titles Features: Editorial board of nationally recognized experts across the spectrum of Cancer Therapeutics In-depth, up-to-date expert reviews and analysis of major new developments in all areas of Cancer Therapeutics Issues edited by an authority in specific subject area Focuses on major topics in Cancer Therapeutics with in-depth articles covering advances in clinical and translational research developments, as well as clinical applications and experience Emphasizes multidisciplinary approaches to research and practice

One of The Wall Street Journal’s 10 Best Nonfiction Books of the Year Philadelphia, 1959: A scientist scrutinizing a single human cell under a microscope detects a missing piece of DNA. That scientist, David Hungerford, had no way of knowing that he had stumbled upon the starting point of modern cancer research— the Philadelphia chromosome. It would take doctors and researchers around the world more than three decades to unravel the implications of this landmark discovery. In 1990, the Philadelphia chromosome was recognized as the sole cause of a deadly blood cancer, chronic myeloid leukemia, or CML. Cancer research would never be the same. Science journalist Jessica Wapner reconstructs more than forty years of crucial breakthroughs, clearly explains the science behind them, and pays tribute—with extensive original reporting, including more than thirty-five interviews—to the dozens of researchers, doctors, and patients with a direct role in this inspirational story. Their curiosity and determination would ultimately lead to a lifesaving treatment unlike anything before it. The Philadelphia Chromosome chronicles the remarkable change of fortune for the more than 70,000 people worldwide who are diagnosed with CML each year. It is a celebration of a rare triumph in the battle against cancer and a blueprint for future research, as doctors and scientists race to uncover and treat the genetic roots of a wide range of cancers.

Written by over 50 internationally distinguished experts, 30 more than the first edition, and contains nine new chapters! Continuing in the esteemed tradition and heralded success of the first edition, Chronic Lymphoid Leukemias, Second Edition offers a full overview of chronic lymphocytic leukemia (CLL) from multiple perspectives-covering all major developments since the previous edition was published eight years ago. Chronicling the complete history and variations of CLL-type leukemia, the Second Edition reviews the origin, nature, and molecular differences between B-CLL and T-CLL/PLL leukemias analyzes core constituents of apoptosis and causes for dysregulation of programmed cell death (PCD) in B-CLL examines recent research on the role cytokines and regulatory molecules may play in cross-cell communication profiles commonly used vectors for somatic gene therapy, as well as the latest advances in genetic engineering and vector design and production utilizes up-to-the-minute techniques such as fluorescence in-situ hybridization (FISH) and comparative genomic hybridization (CGH) to detect genetic abnormalities and aberrations explores current measures of supportive care with splenectomy, cytokine proteins, and intravenous immunoglobulin applications identifies how to manage infectious and psychiatric complications in patients with CLL and much more! Provides contemporary results on the efficacy of nucleoside analog combinations such as ara-C with fludarabine and cladribine and on the emerging nucleosides nelarabine and clofarabine! Copiously supplemented with over 2500 literature references-1000 more than the first edition-Chronic Lymphoid Leukemias, Second Edition fulfills the reference needs of oncologists, hematologists, immunologists, pathologists, infectious disease specialists, internists, molecular biologists, and medical school students in these disciplines.